Mylan wins $106.7M in damages in lawsuit against GSK A jury has ordered GSK (GSK) to pay Mylan (MYL) $106.7M in damages in a breach-of-contract lawsuit related to antidepressant Paroxetine Hydrochloride Extended-Release Tablets. Mylan says it "intends to seek additional relief to further protect its rights."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.